Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Sovaldi/Harvoni

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Sovaldi/Harvoni was produced by Gilead Sciences.

Torrid times at Gilead lead to calls for a major M&A deal

Torrid times at Gilead lead to calls for a major M&A deal

Sales of its hepatitis drugs Sovaldi, Harvoni and Epclusa were down $1.5bn in the same period of 2015 to $3.3bn, with overall revenues down almost 10% to $7.5bn

Gilead’s hepatitis C sales start to slide – the question is how quickly?

Gilead’s hepatitis C sales start to slide – the question is how quickly? The US pharma company has reaped the benefits of stellar sales for its directly-acting HCV therapies since it first launched Sovaldi (sofosbuvir) in 2013 and two-drug follow-up Harvoni

European pharma ‘to grow 3.2% per year by 2022’

European pharma ‘to grow 3.2% per year by 2022’ In hepatitis C, Gilead's Sovaldi (2015: 1.443 bn; 2022: 609m) and its follow-up therapy Harvoni (2015: 2 bn; 2022: 887m) million) will struggle due to price pressure and

FDA approves Gilead's 'universal' hep C combination Epclusa

FDA approves Gilead's 'universal' hep C combination Epclusa Epclusa joins Sovaldi and Harvoni (sofosbuvir/ledipasvir), a product specifically indicated for patients with hepatitis C virus genotype 1 infection, in Gilead's hep C portfolio. ... Sovaldi and Harvoni brought in sales of $5.3bn and $13.9bn respectively

Gilead must pay just $200m for hep C patents, says jury

Gilead must pay just $200m for hep C patents, says jury Merck &Co awarded a 4% royalty rate on sales of Sovaldi and Harvoni. ... Merck had been pushing for a 10% royalty rate on the $20.7bn Gilead had made from sales of two sofosbuvir-based drugs - Sovaldi and Harvoni - between 2013 and 2015, after

1 2 3 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics